With the intensification of global population aging, muscle atrophy, characterized by the loss of muscle mass and function, has become an important health issue affecting
Oral cancer is an increasingly prevalent disease worldwide, with over 300,000 new cases diagnosed each year. Among oral cancers, tongue cancer (TC) is the most
How cellular cleanup systems could hold the key to slowing aging and halting neurodegeneration.
Intellia Therapeutics is the latest CRISPR company resorting to layoffs as investors increasingly turn away from gene editing.The Cambridge, MA-based company announced Thursday that …
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project that’s working with Gilead’s Kite
About three months ago, IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now the company is shelving
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Catalyst Pharmaceuticals’ controversial $375,000 rare autoimmune disease drug now won’t face generic competition from Teva until Feb. 25, 2035, thanks to a patent settlement announced
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The biotech is developing what it calls logic-gated cell